|Bid||1,663.50 x 175400|
|Ask||1,664.00 x 417900|
|Day's Range||1,630.50 - 1,665.00|
|52 Week Range||1,363.00 - 1,745.56|
|PE Ratio (TTM)||48.78|
|Dividend & Yield||1.01 (4.77%)|
|1y Target Est||N/A|
Gilead Sciences Inc said on Tuesday a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies. Gilead, which already has approved treatments for HIV, is pinning its hope on the combination to better compete with Britain's GlaxoSmithKline Plc, which is working on two-drug treatment regimen for controlling the virus behind AIDS. The U.S. drugmaker evaluated the addition of its experimental drug, bictegravir, to emtricitabine/tenofovir alafenamide (FTC/TAF), which are already in use to treat HIV.
The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories
As Novartis considers asset sales that could raise $50 billion, investors are worried any cash raised may give the Swiss drugmaker firepower for another unsuccessful megadeal. Novartis's $52 billion takeover of U.S.-based eye care giant Alcon, completed in 2011, saddled it with a business whose sales and profit have faltered two years running. Now, Chief Executive Joe Jimenez is reviewing Alcon's surgical devices and contact lens businesses, suggesting they could be valued at $25-$35 billion if he unloads them.